Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability

Blood ◽  
2008 ◽  
Vol 111 (9) ◽  
pp. 4700-4705 ◽  
Author(s):  
Tilmann Bochtler ◽  
Ute Hegenbart ◽  
Friedrich W. Cremer ◽  
Christiane Heiss ◽  
Axel Benner ◽  
...  

AbstractChromosomal aberrations (CAs) have emerged as important pathogenetic and prognostic factors in plasma cell disorders. Using interphase fluorescence in situ hybridization (FISH) analysis, we evaluated CAs in a series of 75 patients with amyloid light chain amyloidosis (AL) as compared with 127 patients with monoclonal gammopathy of unknown significance (MGUS). We investigated IgH translocations t(11;14), t(4;14), and t(14;16) as well as gains of 1q21, 11q23, and 19q13 and deletions of 8p21, 13q14, and 17p13, detecting at least one CA in 89% of the patients. Translocation t(11;14) was the most frequent aberration in AL, with 47% versus 26% in MGUS (P = .03), and was strongly associated with the lack of an intact immunoglobulin (P < .001), thus contributing to the frequent light chain subtype in AL. Other frequent aberrations in AL included deletion of 13q14 and gain of 1q21, which were shared by MGUS at comparable frequencies. The progression to multiple myeloma (MM) stage I was paralleled by an increased frequency of gain of 1q21 (P = .001) in both groups. Similar branching patterns were observed in an oncogenetic tree model, indicating a common mechanism of underlying karyotypic instability in these plasma cell disorders.

2007 ◽  
Vol 5 (2) ◽  
pp. 179-187 ◽  
Author(s):  
Raymond L. Comenzo

Amyloidosis is a rare disease in which a specific protein is deposited as aggregated interstitial fibrils that can compromise organ function and lead to death. Immunoglobulin (Ig) light-chain amyloidosis (AL), caused by the monoclonal gammopathy of a plasma cell dyscrasia, is the most common type. A hereditary type is also caused by mutant transthyretin and other proteins. Rarely, a patient with amyloid has both a monoclonal gammopathy and a hereditary protein. In AL, circulating monoclonal Ig light chains can be measured with the free light-chain (FLC) assay and provide a target for therapy to eliminate the underlying plasma cell dyscrasia while supporting the patient's organ function. Amyloid deposits can be resorbed and organ function restored if the amyloid-forming precursor FLC is eliminated. For patients with limited organ involvement, intravenous melphalan in doses from 100 to 200 mg/m2 with autologous stem cell support (SCT) is an effective approach and, when followed at 3 months post-SCT with adjuvant thalidomide and dexamethasone for persistent plasma cell disease, has a 1-year hematologic response rate of 77%. Monthly oral melphalan and dexamethasone for 1 year can also be effective therapy for patients too sick for SCT (67% response rate). Hematologic complete responses are usually durable and result in long-term survival and a variable degree of organ recovery. For patients with advanced cardiac involvement, the prognosis remains guarded even with treatment. Drugs effective in multiple myeloma are usually active in AL, depending on side effects. New agents such as bortezomib and lenalidomide have shown promising activity, and novel antibody-based approaches for imaging amyloid and accelerating removal of deposits are being actively investigated.


2018 ◽  
Vol 12 (3) ◽  
pp. 737-746
Author(s):  
Toshiro Fukui ◽  
Yuji Tanimura ◽  
Yasushi Matsumoto ◽  
Shunsuke Horitani ◽  
Takashi Tomiyama ◽  
...  

Amyloid light-chain (AL) amyloidosis is associated with plasma cell disorder and monoclonal light chains. This type of amyloidosis is the prominent type involving the gastrointestinal tract. Monoclonal gammopathy of undetermined significance (MGUS) is the most common plasma cell disorder and a known precursor of more serious diseases. A 72-year-old male was treated for high blood pressure, diabetes, and gout at the clinic of a private physician. Due to a positive fecal occult blood test discovered during colon cancer screening, he underwent colonoscopy and was diagnosed with adenomatous polyps by biopsies. Two months later, he was referred to our hospital for endoscopic resection of the polyps. Although the polyps were successfully removed, a colonoscopy revealed two types of ulcerative lesions. Immunohistopathological evaluations obtained from these lesions and polyps confirmed amyloid deposition. Although esophagogastroduodenoscopy results were normal, a biopsy specimen from the patient’s stomach showed the same type of amyloid deposition. Immunoelectrophoresis showed M-proteins for anti-IgG-λ in the serum and λ type Bence-Jones protein in the urine. His blood, bone marrow, and urine test results led to a diagnosis of MGUS. A coronary angiography revealed multivessel stenosis, and the patient’s cardiac function improved after coronary artery stenting. Hereafter, a combination therapy with bortezomib, lenalidomide, and dexamethasone is planned. This is a case report of systemic AL amyloidosis caused by MGUS, which was incidentally detected by colonoscopy.


Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 2500-2500 ◽  
Author(s):  
Tilmann Bochtler ◽  
Stefan O. Schonland ◽  
Anna Jauch ◽  
Christiane Heiss ◽  
Axel Benner ◽  
...  

Abstract Introduction: Cytogenetic aberrations (CA) have emerged as important pathogenetic and prognostic factors in plasma cell disorders. However, in AL amyloidosis (AL) only a few reports with small numbers of patients have been published. Methods: Using interphase FISH analysis in CD138+ cells, we evaluated the role of CA in a series of 85 AL patients as compared to 146 patients with a monoclonal gammopathy without treatment requirement in a prospective manner. Our panel included IgH translocations t(11;14), t(4;14), t(14;16) and translocation of 14q32 with an unidentified partner, gains of 1q21, 11q23 and 19q13 as well as deletions of 8p21, 13q14 and 17p13. Using these probes we could detect at least one of these aberrations in 95% of AL and in 88% of the control group. Age, gender and plasma cell content were statistically equally distributed among both groups. Results: The most frequent aberration in AL was t(11;14), which was detected in 45% of AL patients as compared to 26% of the control group (p=0,056). It was strongly associated with the lack of an intact immunoglobulin (p&lt;0,001), thus accounting for the frequent light chain only subtype in AL. Markedly, t(11;14) was more frequently found in combination with gain 11q23 in AL than in the control group (20% versus 6%, p = 0.005). Other frequent aberrations in AL included deletion 13q14 (32%) and gain 1q21 (21%), which were observed in the control group at comparable frequencies (34% and 20%). The overlapping character of the underlying plasma cell disorder in both disease entities was also emphasized by the similarities of branching patterns of the five major CA in cluster analysis applied in 169 patients (figure 1). The relation of clinical parameters and chromosomal aberrations was also evaluated. The analyzed CA had no impact on the organ involvement pattern in AL patients. Conclusions: We observed a high frequency for t(11;14) in AL. Apart from this finding, the cytogenetic patterns known in monoclonal gammopathy of unknown significance and multiple myeloma were widely shared by AL amyloidosis. Figure Figure


Haematologica ◽  
2009 ◽  
Vol 94 (3) ◽  
pp. 439-441 ◽  
Author(s):  
S. O. Schonland ◽  
N. Kroger ◽  
C. Wolschke ◽  
P. Dreger ◽  
A. D. Ho ◽  
...  

Blood ◽  
1998 ◽  
Vol 91 (10) ◽  
pp. 3662-3670 ◽  
Author(s):  
Raymond L. Comenzo ◽  
Evan Vosburgh ◽  
Rodney H. Falk ◽  
Vaishali Sanchorawala ◽  
Johann Reisinger ◽  
...  

Abstract AL (amyloid light-chain) amyloidosis is an uncommon plasma cell disorder in which depositions of amyloid light-chain protein cause progressive organ failure and death in a median of 13 months. Autologous stem-cell transplantation is effective therapy for multiple myeloma and therefore, we evaluated its efficacy for AL amyloidosis. Patients with adequate cardiac, pulmonary, and renal function had stem cells mobilized with granulocyte-colony stimulating factor and were treated with dose-intensive intravenous melphalan (200 mg/m2). Response to therapy was determined by survival and improvement of performance status, complete response or persistence of the clonal plasma cell disorder, and change in the function of organs involved with amyloid at baseline. We enrolled 25 patients with a median age of 48 years (range, 29-60), all of whom had biopsy-proven amyloidosis with clonal plasma cell disorders. Twenty-two (88%) were Southwest Oncology Group performance status 1 or 2 within a year of diagnosis, and 16 (64%) had received no prior therapy. Predominant amyloid-related organ involvement was cardiac (n = 8), renal (n = 7), hepatic (n = 6), neuropathic (n = 3), and lymphatic (n = 1). Fifteen patients had one or two organ systems involved, whereas 10 had three or more involved. With a median follow-up of 24 months (12-38), 17 of 25 patients (68%) are alive, and the median survival has not been reached. Thirteen of 21 patients (62%) evaluated 3 months posttransplant had complete responses of their clonal plasma cell disorders. Currently, two thirds of the surviving patients (11 of 17) have experienced improvements of amyloid-related organ involvement in all systems, whereas 4 of 17 have stable disease. The improvement in the median performance status of the 17 survivors at follow-up (0 [range, 0-3]) is statistically significant versus baseline (2 [range, 1-3]; P < .01). Significant negative prognostic factors with respect to overall survival include amyloid involvement of more than two major organ systems and predominant cardiac involvement. Three patients have experienced relapses of the clonal plasma cell disorder at 12 and 24 months. Dose-intensive therapy should currently be considered as the preferred therapy for patients with AL amyloidosis who meet functional criteria for autologous transplantation.


Blood ◽  
1998 ◽  
Vol 91 (10) ◽  
pp. 3662-3670 ◽  
Author(s):  
Raymond L. Comenzo ◽  
Evan Vosburgh ◽  
Rodney H. Falk ◽  
Vaishali Sanchorawala ◽  
Johann Reisinger ◽  
...  

AL (amyloid light-chain) amyloidosis is an uncommon plasma cell disorder in which depositions of amyloid light-chain protein cause progressive organ failure and death in a median of 13 months. Autologous stem-cell transplantation is effective therapy for multiple myeloma and therefore, we evaluated its efficacy for AL amyloidosis. Patients with adequate cardiac, pulmonary, and renal function had stem cells mobilized with granulocyte-colony stimulating factor and were treated with dose-intensive intravenous melphalan (200 mg/m2). Response to therapy was determined by survival and improvement of performance status, complete response or persistence of the clonal plasma cell disorder, and change in the function of organs involved with amyloid at baseline. We enrolled 25 patients with a median age of 48 years (range, 29-60), all of whom had biopsy-proven amyloidosis with clonal plasma cell disorders. Twenty-two (88%) were Southwest Oncology Group performance status 1 or 2 within a year of diagnosis, and 16 (64%) had received no prior therapy. Predominant amyloid-related organ involvement was cardiac (n = 8), renal (n = 7), hepatic (n = 6), neuropathic (n = 3), and lymphatic (n = 1). Fifteen patients had one or two organ systems involved, whereas 10 had three or more involved. With a median follow-up of 24 months (12-38), 17 of 25 patients (68%) are alive, and the median survival has not been reached. Thirteen of 21 patients (62%) evaluated 3 months posttransplant had complete responses of their clonal plasma cell disorders. Currently, two thirds of the surviving patients (11 of 17) have experienced improvements of amyloid-related organ involvement in all systems, whereas 4 of 17 have stable disease. The improvement in the median performance status of the 17 survivors at follow-up (0 [range, 0-3]) is statistically significant versus baseline (2 [range, 1-3]; P < .01). Significant negative prognostic factors with respect to overall survival include amyloid involvement of more than two major organ systems and predominant cardiac involvement. Three patients have experienced relapses of the clonal plasma cell disorder at 12 and 24 months. Dose-intensive therapy should currently be considered as the preferred therapy for patients with AL amyloidosis who meet functional criteria for autologous transplantation.


Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 1896-1896
Author(s):  
Raul C. Braylan ◽  
Karina Baggiani ◽  
Tiana Golding ◽  
Eric Kroman ◽  
Michael L. Miller ◽  
...  

Abstract Abstract 1896 Flow cytometric analysis (FCM) is now considered an essential tool for the identification of malignant hemopoietic and lymphoid cells, and it is particularly useful in evaluating plasma cell clonality to differentiate normal from neoplastic plasma cells (PC). Neoplastic PC typically show loss of CD19 and aberrant expression of markers such as CD56 and CD117, but the demonstration of an expansion of PC containing a single immunoglobulin light chain (monotypic or clonal expansion) is critical for determining the nature of a plasma cell population. Genetic abnormalities are becoming essential markers for prognosis of plasma cell disorders (PCD). Because of the relatively low proliferation or low representation of PC in the sample, FISH rather than conventional cytogenetics is used routinely or the detection of karyotypic abnormalities in PCD and the use of FISH in plasma cell-enriched preparations has improved the sensitivity of detection of genetic abnormalities in these disorders. We wished to determine how often FCM would detect monoclonal cells in marrows with genetic abnormalities observed by FISH. For this purpose, we analyzed marrow samples that were either non-enriched or enriched for PC using immunomagnetic beads for cell separation. From February 2009 until present, we studied marrows sent to our laboratory for diagnostic purposes from 158 patients who either had a clinical or laboratory abnormality suggestive of or consistent with PCD, or their marrows demonstrated immunophenotypic abnormalities of PC. The FCM consisted of a simultaneous determination of surface CD45, CD19, CD38, CD56 and intracytoplasmic kappa and lambda immunoglobulin (Ig) light chains in a single tube, using a Canto II cytometer (BD). Between 105 and 3×105 cells were analyzed in each case. Clonal expansions were detected based on the Ig light chain expression in cells selected as normal or abnormal plasma cells by their surface phenotype. FISH analysis was performed using Abbott probes for CEP 7, CEP 9, CCND1/IgH, RB1, and p53 on both enriched and non-enriched interphase cells. FISH samples were processed according to standard procedures and 200 cells were analyzed for each probe. Plasma cell enrichment was performed by incubating marrow cells with CD138-coated immunomagnetic beads, and isolating them on Miltenyi separation columns using an auto MACS Pro Separator. Of the 158 samples studied, 52 underwent plasma cell enrichment. Enrichment was performed on samples with less than 8% PC as assessed by FCM. The fraction of PC in enriched samples was approximately 10 times greater than those in non-enriched samples. FISH abnormalities were detected in enriched samples from cases that contained as low as 0.04% PC prior to enrichment. The majority of the enriched samples that showed FISH abnormalities exhibited multiple FISH alterations, the most common being additional copies of CEP 7, CEP 9 and CCND1 DNA sequences, and deletion of RB1 and p53. Of the 158 samples, 46 (29%) were found to be polyclonal by FCM and normal by FISH. These included 8 samples enriched for PC. Of the 69 non-enriched samples only 33 (48%) demonstrated FISH abnormalities. Of these abnormal samples, 32 (97%) were monoclonal by FCM. Among the 43 samples that underwent plasma cell enrichment, 37 (86%) demonstrated FISH abnormalities. Of these enriched abnormal samples, 34 (92%) were shown to be monoclonal by FCM. Our results showed that, confirming previous observations, targeted FISH analysis using plasma cell enrichment increases the detection frequency of abnormalities in PCD, which can be found in the majority of cases. This study also showed that FCM detected monoclonality in the vast majority of samples of PCD that demonstrated FISH abnormalities, whether or not they were enriched for PC, validating the clinical utility of FCM in the routine diagnostic evaluation of patients with PCD. Disclosures: No relevant conflicts of interest to declare.


2021 ◽  
Vol 10 (1) ◽  
Author(s):  
Linchun Xu ◽  
Yongzhong Su

AbstractImmunoglobulin light chain amyloidosis (AL) is an indolent plasma cell disorder characterized by free immunoglobulin light chain (FLC) misfolding and amyloid fibril deposition. The cytogenetic pattern of AL shows profound similarity with that of other plasma cell disorders but harbors distinct features. AL can be classified into two primary subtypes: non-hyperdiploidy and hyperdiploidy. Non-hyperdiploidy usually involves immunoglobulin heavy chain translocations, and t(11;14) is the hallmark of this disease. T(11;14) is associated with low plasma cell count but high FLC level and displays distinct response outcomes to different treatment modalities. Hyperdiploidy is associated with plasmacytosis and subclone formation, and it generally confers a neutral or inferior prognostic outcome. Other chromosome abnormalities and driver gene mutations are considered as secondary cytogenetic aberrations that occur during disease evolution. These genetic aberrations contribute to the proliferation of plasma cells, which secrete excess FLC for amyloid deposition. Other genetic factors, such as specific usage of immunoglobulin light chain germline genes and light chain somatic mutations, also play an essential role in amyloid fibril deposition in AL. This paper will propose a framework of AL classification based on genetic aberrations and discuss the amyloid formation of AL from a genetic aspect.


2018 ◽  
Vol 11 (2) ◽  
pp. 105-111 ◽  
Author(s):  
Lindsay Hammons ◽  
Ruta Brazauskas ◽  
Marcelo Pasquini ◽  
Mehdi Hamadani ◽  
Parameswaran Hari ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document